Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Articles

Decreased Dihydropyridine Receptor Number in Hypertensive Rat Vascular Muscle Cells

Kent Hermsmeyer, Anita C. White, David J. Triggle
https://doi.org/10.1161/01.HYP.25.4.731
Hypertension. 1995;25:731-734
Originally published April 1, 1995
Kent Hermsmeyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita C. White
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Triggle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract To further investigate the altered function of Ca2+ channels in vascular muscle cells in hypertension, a novel fluorescently labeled dihydropyridine was used with ultrahigh-sensitivity photometry to study dihydropyridine binding sites on the surface membrane of living vascular muscle cells from stroke-prone spontaneously hypertensive rats and their normotensive controls. Fluorescent nitrobenzoxadiazol-6-dihydropyridine in concentrations of 1 to 100 nmol/L bound specifically to vascular muscle cells’ Ca2+ channels, and was displaced by the unlabeled dihydropyridine analogue or nisoldipine (10 μmol/L). Stroke-prone spontaneously hypertensive rat vascular muscle cells showed significantly decreased binding of nitrobenzoxadiazol-6-dihydropyridine compared with normotensive National Institutes of Health rats. Decreased binding of dihydropyridine by vascular muscle cells from stroke-prone spontaneously hypertensive rats (cells that in other studies show increased Ca2+ channel function) indicates a change in channel regulation that is possibly due to a deficiency in the inactivation mechanism, consistent with our earlier electrophysiological studies reporting deficiencies in Ca2+-dependent inactivation in genetic hypertension. These data demonstrate decreased numbers of localized sites of dihydropyridine binding on the sarcolemma of living vascular muscle cells, and support the hypothesis that Ca2+ channel alterations may significantly contribute to the molecular etiology of genetic hypertension.

  • Calcium channels
  • rats, inbred SHR
  • sarcolemma
  • binding sites
  • hypertension, genetic

Many unanswered questions remain about how Ca2+ crosses cell membranes, although knowledge about the Ca2+ channels that account for the electrically gated part of Ca2+ influx has progressed remarkably in the past decade. Combined electrophysiological and optical techniques have revealed that Ca2+ channels signal many of the functions in a variety of excitable and secretory cells (reviewed by Tsien et al1 and Bean2 ). The Ca2+ channel appears to be an elemental structure consisting of a multipart Ca2+ channel protein3 that flickers open and closed within milliseconds to admit trigger amounts of Ca2+. The Ca2+ channel molecule can be rapidly gated by voltage to increase, by several hundredfold, the rate of Ca2+ ion entry,1 4 and is the same 1,4-dihydropyridine–sensitive Ca2+ channel that is important in vascular muscle cells (VMC) for total peripheral resistance.5

For several reasons, it is important to explore the spatial definition of Ca2+ channels by directly visualizing dihydropyridine (DHP) binding sites. Examples are such questions as whether there are different populations of Ca2+ channels, possible spatial bases for channel interactions, and multiple sites of action of Ca2+ channel blockers. The high affinity and selectivity of DHP for L-type Ca2+ channels6 has been the basis for the characterization and isolation of one of the L-type Ca2+ channel proteins.7 This study uses a newly synthesized fluorescent DHP, high sensitivity detectors, and digital image acquisition to examine the cellular distribution of DHP binding on the sarcolemma of living cells.

Alterations in Ca2+ channels are hypothesized to contribute to hypertension,5 8 9 and stroke-prone spontaneously hypertensive rats (SHRSP) show the most extreme example of the high blood pressure exaggeration.10 To compare Ca2+ channel DHP binding in SHRSP with that in VMC from normotensive outbred-panel-of-strains National Institutes of Health rats (N/nih) with high sensitivity and resolution, we used two optical systems. One is a literal photon-counting measurement made with a two-stage microchannel plate camera (Hamamatsu) that is orders of magnitude more sensitive (10−9 lux) than other cameras. The other system is the Leitz laser scan confocal microscope (CLSM), which was selected for its high resolution in the z axis as well as in the x and y axes. With photon counting, the low background and ultrahigh sensitivity permit detection of DHP binding that tentatively represents only a few Ca2+ channels. Images acquired by the photon-counting detector allow femtomolar or even attomolar binding quantification in real time, as well as visualization of composites of Ca2+ channels. The z-axis resolution in this whole-field (0.8 NA water immersion) image is calculated to be 12 μm. The CLSM is less sensitive than the photon-counting detector, but offers high z-axis resolution (≤0.5 μm with the 1.0 NA water immersion objective). The probe used to explore sites of high-affinity binding of DHP is the brightly fluorescent nitrobenzoxadiazol (NBD)-labeled DHP custom synthesized for this purpose. The NBD-6-DHP probe is closely related to nitrendipine. A nonfluorescent analogue of NBD-6-DHP was also available with the same structure but lacking the NBD fluorescent group.

Methods

Primary cultures of aortic and azygos vein vascular muscle cells were prepared from neonatal (1 to 4 days old) SHRSP and outbred normotensive control N/nih. Systolic blood pressures of SHRSP averaged 196±11 mm Hg at 8 to 12 weeks, and averages for N/nih were 122±8 mm Hg (n=30 of each animal type). Aortas and azygos veins were dissected from SHRSP and N/nih and placed in 25°C CV3M solution, which consists of 85% minimal essential medium and 15% horse serum (vol/vol), to which is added 4 mmol/L l-glutamine, 20 mmol/L HEPES at pH 7.3, 4 mmol/L NaHCO3, and 20 μg/mL gentamicin.11 After the rinse in CV3M, vessel segments were soaked for 10 minutes in KG solution, which consists of (mmol/L) potassium glutamate 140, HEPES 25 (final pH 7.3), NaH2PO4 0.5, NaHCO3 4, glucose 5.5, and phenol red 0.014. Pieces of each blood vessel type from all the pups of a single litter were minced into 1-mm (maximum dimension) pieces with fine dissecting scissors and incubated at 37°C for 30 minutes in collagenase (30 mg in 10 mL KG solution containing 0.1 μmol/L Ca2+). After 30 minutes, the collagenase supernatant was discarded and the sediment was sequentially exposed to three to four incubations of 1 mg/mL trypsin in KG solution for 15 minutes. After each 15-minute incubation in trypsin, the supernatant was removed and placed in 25 mL CV3M on ice. Supernatants were centrifuged at 200g and 4°C for 15 minutes and the pellet was resuspended in 10 mL ice-cold CV3M, which was further centrifuged (always at 4°C) for 10 minutes at 200g. After the supernatant was removed, the remaining cells were resuspended in 10 mL 37°C CV3M, transferred to Falcon plastic T25 tissue culture flasks (Becton Dickinson and Co) for 1 hour of sedimentation, and placed in the incubator at 37°C. After 1 hour, nonattached VMC were transferred to centrifuge tubes, separated at 200g, resuspended in CV3M plus 250 μmol/L bromodeoxyuridine, diluted to a density of about 70 000 cells/mL, and plated on clean 9×22 mm glass coverslips (Corning, Inc) and 35-mm sterile Falcon plastic Petri dishes. VMC were kept in 95% air, 5% CO2 at 95% relative humidity and 37°C for 2 to 7 days. Bromodeoxyuridine and gentamicin were always removed at least 24 hours before contracting VMC were selected for the binding experiments. Cell culture solutions were from GIBCO, collagenase was from Worthington, and other solutions were from Sigma Chemical Co.

Fluorescence labeling of the VMC was carried out with NBD-6-DHP, the nitrobenzoxadiazol fluorescent derivative of a DHP similar to nitrendipine, but with a CF3 group replacing the NO2 group to add photostability (Fig 1⇓). NBD-6-DHP was synthesized by Dr N. Baindur (N. Baindur, unpublished data, 1994). Living, contracting VMC were optimally labeled in room-temperature (22°C) ionic solution for mammals (ISM) (consisting of [mmol/L] NaCl 130, NaHCO3 16, NaH2PO4 0.5, KCl 4.7, CaCl2 1.8, MgCl2 0.4, MgSO4 0.4, HEPES 13, and dextrose 5.5, pH 7.3 to 7.4) with a 20-minute exposure to 10 to 100 nmol/L NBD-6-DHP. VMC were loaded by stopping the flow through the 300-μL–capacity laminar flow chamber for 10 minutes, during which 20 μL of 0.1 to 100 nmol/L NBD-6-DHP was placed as a drop over the cells in the field of the microscope (Carl Zeiss, Inc). After 10 minutes of loading with stopped flow, suffusion was restored and 10 minutes allowed for washout of excess fluorescence. For definition of nonspecific binding, cells were exposed to 10 μmol/L unlabeled DHP analogue or 1 to 10 μmol/L nisoldipine after the 15 minutes of preincubation with NBD-6-DHP. For optical quantitation and digital image acquisition, cells were briefly exposed (for 10 seconds or less except as noted) to excitation through fluorescence filters, by use of a Zeiss 25×/0.8 NA water objective, with two layers of Omega 485DF22 (485±11 nm) excitation filters, with emission separated from excitation by a 505-nm DRLP dichroic mirror, and viewed through an Omega 530DF30 (530±15 nm) emission filter. In addition, four separate layers of ultraviolet and infrared blocking filters were included in the light path to protect the cells and probe against both ultraviolet and infrared illumination by a suppression factor of more than 108. Measurements of fluorescence intensity were continued for at least a 10-minute period, with illumination for only 10-second periods, never exceeding six times (except as noted). Masking of the illumination beam limited the excited area to the part of the cell being quantified (typically <1000 μm2). The fluophor was stable for at least 60 seconds of cumulative illumination, during which fading of fluorescence was not detectable. Quantitation was carried out using a Hamamatsu (C1966-20) two-stage microchannel plate camera at its highest sensitivity of 10−9 lux, with data digitally acquired by a Perceptics Biovision image processor. Averages of 30 frames (1 second) provided the best measure of Ca2+ channel binding while not interfering with the dynamics of binding. Longer integrations of up to 30 seconds for higher sensitivity were used only for lowest label concentrations (as noted). Confocal images were analyzed by use of a Leitz CLSM (Leica) with the 488-nm laser and a Leitz 50×/1.00 NA water objective. Quantitation of fluorescence was carried out by calibration with known standards, application of background and field scan corrections, and resulting look-up tables for each cell. The calibration procedure is extensive (K.H. et al, unpublished data, 1994); in brief, it consists of NBD-6-DHP measurements in precision 20-μm path length glass capillary tubing (Vitro Dynamics, Inc) filled with the label in perfusion solution and in a second set in which low concentrations of NDB-6-DHP in alcohol are dried on the glass to correspond with sarcolemma labeling. Surface layer fluorescence was expressed as number of moles per square micron (the latter being the approximate area of a fluorescent cluster) and as the absolute amount of fluorphor, stated in moles. Conversion to Bmax values was based on Scatchard curve intercepts and expressed as moles of binding site per entire cell. Statistical comparisons were made using ANOVA with Scheffé tests, selecting P<.05 as the criterion for significance.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Top, diagram shows structure of the fluorescent label 7-nitrobenz-2-oxa-1,3-diazol-4-yl-6-dihydropyridine (DHP-6-NBD). Bottom, spectra for excitation and emission.

Results

Fig 2⇓ shows images of VMC at saturation labeling at 22°C and 30 minutes for SHRSP and N/nih. Fig 2A⇓ shows an N/nih aortic VMC that is more strongly labeled than that from SHRSP (Fig 2B⇓), and Fig 2C⇓ is an N/nih azygos vein VMC that has more NDB-6-DHP binding than that from SHRSP (Fig 2D⇓) after exposure to 10 nmol/L fluorescent label. These four VMC images are representative of N/nih labeling compared with SHRSP labeling in 9 to 12 studies with each cell type. There were fewer DHP receptors in both the aorta and the azygos vein VMC of SHRSP, as shown in Fig 3⇓, which is a plot of specific binding isotherms for an example of each blood vessel type. Half-saturation was reached by approximately 4 nmol/L of free DHP for all four cell types. Specific binding in N/nih was 81±2% for aorta and 89±4% in azygos vein VMC, and in SHRSP it was 78±5% in aorta and 90±4% in azygos vein VMC (n=8 for each of the four types of VMC). Saturation occurred at about 40 nmol/L for each type, but with a different maximum, which was generally greater than the complete curves in single VMC shown in Fig 3⇓. In Fig 3⇓, only one cell for each of the four types is shown. Scatchard fits of the fluorescence binding data showed differences in the number of DHP receptors, but no difference in affinity (Table⇓). Data in the Table⇓ represent composite averages by cell type for all cells studied. Bmax was decreased by 50% in aorta and 43% in azygos vein VMC of SHRSP (both significantly different). Ca2+ channel labeling was nonuniform at all concentrations in both whole-field and confocal images, suggesting that clustering of Ca2+ channels is the predominant pattern. In contrast, nonspecific fluorescence showed a random distribution in each of 32 cells.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Photographs of whole-field fluorescence at NA=0.8 show that binding of fluorescent dihydropyridine to vascular muscle cells was greater in normotensive National Institutes of Health rats (N/nih) than in stroke-prone spontaneously hypertensive rats (SHRSP) for both aorta and azygos vein. A, N/nih aorta; B, SHRSP aorta; C, N/nih azygos vein; and D, SHRSP azygos vein. Vascular muscle cells contained clusters of dihydropyridine fluorescence, which were even more evident in confocal images (not shown), nearly all of which (>90%) could be displaced by 10 μmol/L nisoldipine. Both blood vessels were less labeled with the dihydropyridine probe in SHRSP than in N/nih. These data are representative of 9 to 12 experiments for each of four cell types.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Line graph shows that stroke-prone spontaneously hypertensive rat (SP-SHR) saturation isotherms at 22°C were depressed compared with normotensive National Institutes of Health rat (N/nih) saturation isotherms for both aorta and azygos vein vascular muscle cells. The plots shown are from one cell for each curve, and at 1, 2, and 5 nmol/L were integrated for 30 seconds (with fluorescence fading). Although these curves show a smaller decrease than the averages from eight cells presented in the Table⇓, the direction of the difference was consistent. Binding sites are expressed as moles per cell. Conversion depended on fluorescence standards prepared as ultrathin layers on glass, with number of moles rather than moles per milliliter as the resulting unit. AFU indicates arbitrary fluorescence units integrated over one cell.

View this table:
  • View inline
  • View popup
Table 1.

Dissociation Constants and Numbers of Receptors

Ca2+ channel clusters were observed at certain points on the sarcolemma, and were clearly not internal or vesicular. Intense fluorescent labeling of areas of various sizes were found over the VMC surface in these whole-field (nonconfocal) images. DHP binding clusters were localized to peripheral (sarcolemmal) sites, as shown by examination with confocal laser scanning. No internalization of fluorescence was detected during the 30-minute observation period, suggesting that all label was at the surface membrane. Specificity of the labeling was additionally implied by displacement to less than 10% of the maximum in 10 minutes on exposure to either nonfluorescent DHP or nisoldipine at 10 μmol/L.

The Table⇑ summarizes binding differences of SHRSP compared with N/nih VMC. Although binding occurs with the same affinity in SHRSP and N/nih VMC, there are significantly fewer NBD-6-DHP binding sites in both aorta and azygos vein VMC of SHRSP compared with N/nih. The data suggest that the number of DHP binding sites per VMC may be on the order of several thousand, with a lower number of Ca2+ channels associated with VMC of genetically hypertensive rats. The difference is significant at P<.05.

Discussion

These experiments demonstrate differences in specific binding of the novel fluorescent probe NBD-6-DHP to the surface membrane of intact, contracting VMC. Decreased binding of DHP to SHRSP VMC compared with N/nih VMC suggests a deficiency in function of Ca2+ channels, probably at the inactivation gate, where Ca2+ antagonists are believed to bind to the Ca2+ channel.3 DHP affinity for VMC Ca2+ channels in these normally polarized cells was lower than under depolarized conditions, such as in broken cell preparations.6 7 Membrane potential has been measured as −45 to −50 mV in isolated, cultured rat aortic and azygos vein VMC,11 and could account for a 5- to 10-fold lower binding affinity. Fluorescent DHP label was displaced by nisoldipine at 1 to 10 μmol/L, suggesting specific competition for functional DHP binding sites. Nisoldipine was more effective in displacing fluorescent DHP than was the unlabeled analogue, probably reflecting a higher affinity of nisoldipine for these Ca2+ channel binding sites (N. Baindur et al, unpublished data, 1994).

SHRSP show exaggerated blood pressures and correspondingly exaggerated Ca2+ currents compared with either their N/nih controls or the less hypertensive SHR from which their strain was derived.10 Although our hypothesis was that Ca2+ channel number in SHRSP would be increased, we found the opposite to be the case. Fundamental alterations in the Ca2+ channel governing inactivation may be responsible. Studies of Ca2+ channel function have shown electrophysiological manifestations of a compromised inactivation process.9 10 12 13 Furthermore, evidence from studies of Ca2+ agonists that contraction on exposure to the agonist Bay k8644 is stronger in hypertension would also be consistent with deficient inactivation.6 7 Perhaps Ca2+ channels with slowed inactivation might downregulate through a feedback control process not yet recognized.14 These data thus suggest a second hypothesis, that Ca2+ channel inactivation (perhaps at Ca2+ antagonist binding sites) may be diminished in genetic hypertension, at least in these rat genetic models. If this is the case, the notable efficacy of Ca2+ antagonists in reducing blood pressure in SHRSP and SHR, despite decreased binding, suggests the fundamental importance of even partial inhibition of Ca2+ influx in VMC.

Acknowledgments

This study was supported by National Institutes of Health grant HL-38537 and by Miles Laboratories, New Haven, Conn.

References

  1. ↵
    Tsien RW, Ellinor PT, Horne WA. Molecular diversity of voltage-dependent Ca2+ channels. Trends Physiol Sci. 1991;12:349-354.
  2. ↵
    Bean BP. Classes of calcium channels in vertebrate cells. Annu Rev Physiol. 1989;51:367-384.
    OpenUrlCrossRefPubMed
  3. ↵
    Hofmann F, Biel M, Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci. 1994;17:399-418.
    OpenUrlCrossRefPubMed
  4. ↵
    Catterall WA. Structure and function of voltage-gated ion channels. Trends Neurosci. 1993;16:500-506.
    OpenUrlCrossRefPubMed
  5. ↵
    Rusch NJ, Hermsmeyer K. Vascular muscle Ca2+ channels in hypertension. In: Coca A, Garay RP, eds. Ion Transport in Hypertension: New Perspectives. Boca Raton, Fla: CRC Press; 1994;197-227.
  6. ↵
    Triggle DJ. Calcium channel drugs: structure-function relations and selectivity of action. J Cardiovasc Pharmacol. 1991;18(suppl 10):S1-S6.
  7. ↵
    Triggle DJ. Calcium, calcium channels, and calcium antagonists. Drugs Dev. 1993;2:3-13.
  8. ↵
    Hermsmeyer K. Differences of calcium channels in vascular muscle in hypertension. Am J Hypertens. 1991;4:412S-415S.
    OpenUrlPubMed
  9. ↵
    Hermsmeyer K, Bian K. Calcium channel hypothesis in hypertension. J Vasc Med Biol. 1991;3:219-222.
  10. ↵
    Self DA, Bian K, Mishra SK, Hermsmeyer K. Stroke-prone SHR vascular muscle Ca2+ current amplitudes closely correlate with lethal increases in blood pressure. J Vasc Res. 1994;31:359-366.
    OpenUrlPubMed
  11. ↵
    Hermsmeyer K, Mason R. Norepinephrine sensitivity and desensitization of cultured single vascular muscle cells. Circ Res. 1982;50:627-632.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Rusch NJ, Hermsmeyer K. Calcium currents are altered in the vascular muscle cell membranes of spontaneously hypertensive rats. Circ Res. 1988;63:997-1002.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Hermsmeyer K, Rusch NJ. Calcium channel alteration in genetic hypertension. Hypertension. 1989;14:453-456.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Ferrante J, Triggle DJ. Drug and disease induced regulation of voltage-dependent calcium channels. Pharmacol Rev. 1990;42:29-44.
    OpenUrlPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
April 1995, Volume 25, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Decreased Dihydropyridine Receptor Number in Hypertensive Rat Vascular Muscle Cells
    Kent Hermsmeyer, Anita C. White and David J. Triggle
    Hypertension. 1995;25:731-734, originally published April 1, 1995
    https://doi.org/10.1161/01.HYP.25.4.731

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Decreased Dihydropyridine Receptor Number in Hypertensive Rat Vascular Muscle Cells
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Decreased Dihydropyridine Receptor Number in Hypertensive Rat Vascular Muscle Cells
    Kent Hermsmeyer, Anita C. White and David J. Triggle
    Hypertension. 1995;25:731-734, originally published April 1, 1995
    https://doi.org/10.1161/01.HYP.25.4.731
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured